Large-scale testing (Phase 3)Study completedNCT03703310
What this trial is testing
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Who this might be right for
Basal Cell Nevus Syndrome
Sol-Gel Technologies, Ltd. 174